| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/RHEUMATOLOGY/KEV019 |
| P698 | PubMed publication ID | 25922549 |
| P50 | author | Cem Gabay | Q66753936 |
| P2093 | author name string | Almut Scherer | |
| Axel Finckh | |||
| Myriam Riek | |||
| SCQM collaborating physicians | |||
| P2860 | cites work | Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study | Q24630541 |
| Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) | Q24631295 | ||
| Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis | Q26852235 | ||
| EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Q26859134 | ||
| Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries | Q33767771 | ||
| Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. | Q33873068 | ||
| Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
| Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register | Q34623922 | ||
| Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register | Q34897423 | ||
| Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study | Q35638208 | ||
| Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab | Q35954629 | ||
| Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists | Q36013844 | ||
| Electronic monitoring of oral therapies in ethnically diverse and economically disadvantaged patients with rheumatoid arthritis: consequences of low adherence | Q36950780 | ||
| The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis | Q38065934 | ||
| The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. | Q38129037 | ||
| Biological agents in monotherapy for the treatment of rheumatoid arthritis | Q38203842 | ||
| Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study | Q42674160 | ||
| Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial | Q44165611 | ||
| Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study | Q44221023 | ||
| Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration | Q44376103 | ||
| Bias and efficiency of multiple imputation compared with complete-case analysis for missing covariate values | Q44393982 | ||
| Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs? | Q44398965 | ||
| P433 | issue | 9 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 1664-1672 | |
| P577 | publication date | 2015-04-27 | |
| P1433 | published in | Rheumatology | Q7320492 |
| P1476 | title | Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry | |
| P478 | volume | 54 |
| Q91944393 | A Comparative Study to Assess the Efficacy, Safety, and Immunogenicity of YLB113 and the Etanercept Reference Product for the Treatment of Patients with Rheumatoid Arthritis |
| Q90215037 | Assessments of the unmet need in the management of patients with rheumatoid arthritis: analyses from the NOR-DMARD registry |
| Q30234303 | Biologics registers in RA: methodological aspects, current role and future applications |
| Q28066250 | Combination therapy with biologic agents in rheumatic diseases: current and future prospects |
| Q58750029 | Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases |
| Q59329016 | Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries |
| Q59459228 | Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic d |
| Q61812081 | Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time |
| Q52653996 | Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study. |
| Q64053097 | Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis-the ANSWER cohort study |
| Q64062693 | Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study |
| Q37085666 | Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study |
| Q37587403 | Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study |
| Q38828876 | Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis |
| Q90415257 | Multicenter Cross-sectional Study of Patients with Rheumatoid Arthritis in Greece: Results from a cohort of 2.491 patients |
| Q92625428 | Novel DMARD monotherapy in rheumatoid arthritis |
| Q39371685 | Novel treatment strategies in rheumatoid arthritis. |
| Q37309669 | Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study |
| Q92463387 | Routine Assessment of Patient Index Data 3 (RAPID3) alone is insufficient to monitor disease activity in rheumatoid arthritis in clinical practice |
| Q94450976 | Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort |
| Q54998113 | The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. |
| Q47693399 | Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. |
| Q31122982 | Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria |
Search more.